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RemodelingTeriparatide is a drug that is used to increase bone remodeling, formation, and density for the treatment of
osteoporosis. We present three cases of patients with a femoral insufﬁciency fracture. The patients were admin-
istered teripatatide in an attempt to treat severe osteoporosis and to enhance fracture healing.We found several
radiographic features around the femoral fractures during the healing period. 1) Callus formation was found at a
very early stage in the treatment. Teriparatide substantially increased the unusually abundant callus formation
around the fracture site at 2 weeks. Moreover, this callus formation continued for 8 weeks and led to healing
of the fracture. 2) Abundant callus formation was found circumferentially around the cortex with a ‘cloud-like’
appearance. 3) Remodeling of the teriparatide-induced callus formation was found to be part of the normal frac-
ture healing process. After 1 year, normal remodelingwas observed on plain radiographs. These ﬁndings indicate
that teriparatide can be used as an adjuvant therapy in the management of femoral insufﬁciency fractures.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Teriparatide is a synthetic polypeptide hormone that contains the
1–34 amino acid fragment of the human parathyroid hormone. It has
been shown to increase bone remodeling, formation, and density for
the treatment of osteoporosis, and it reduces the risk of vertebral and
nonvertebral fractures (Neer et al., 2001; Jiang et al., 2003). Moreover,
it has been shown that teriparatide also accelerates fracture healing by
improving the biomechanical properties of the fracture callus, increas-
ing bone remodeling (Bukata and Puzas, 2010; Reynolds et al., 2009).
This effect has been observed in several clinical case reports and pro-
spective randomized control studies (Aspenberg et al., 2010; Peichl
et al., 2011); however, the radiographic features of teriparatide-
induced fracture healing have not been precisely described. We report
the radiographic features of teriparatide-induced healing of femoral in-
sufﬁciency fractures, including periprosthetic fractures.
2. Case reports
2.1. Case 1
An 88-year-old woman sustained a supracondylar fracture of her
right femur after falling from the bed. She had a previous history of tho-
racic and lumbar spine multiple compression fractures, which were
treated conservatively. She had nohistory of treatment for osteoporosis.urgery, Kyoto CityHospital, 1-2,
pan.
. This is an open access article underWe started to treat this fracture conservatively and initiated administra-
tion of teriparatide (20 μg subcutaneous injection daily) in an attempt to
treat severe osteoporosis and to enhance fracture healing. A plain radio-
graph after 2 weeks showed obvious callus formation around the frac-
ture site, and after 8 weeks, abundant ‘cloud-like’ bridging callus
formation was observed (Fig. 1a). Callus formation with a ‘cloud-like’
appearance was clearly visualized around the fracture site by CT scan
taken at 4 weeks (Fig. 1b). We allowed the patient to start range-of-
motion exercises for the right knee joint after 5 weeks and partial
weight bearing after 7 weeks. No side effects attributable to the drug
were observed during treatment.
2.2. Case 2
A 96-year-old woman sustained a right periprosthetic femoral frac-
ture of type B1 (according to the Vancouver classiﬁcation (Duncan and
Masri, 1995)) after she fell and landed her right side. She had previously
undergone a right bipolar hemiarthroplasty 10 years earlier for a femo-
ral neck fracture and had been ambulatingwell prior to her fall. Medical
history was signiﬁcant for diabetesmellitus. She had a previous fracture
of left femur, which was treated with surgical treatment. She had no
history of treatment for osteoporosis. This periprosthetic fracture
was treated with locking compression plate ﬁxation. After surgery, we
initiated administration of teriparatide to treat severe osteoporosis
and to accelerate fracture healing. Two weeks after initiation of
teriparatide therapy, a plain radiograph showed obvious callus forma-
tion around the fracture site, and after 8 weeks, abundant callus forma-
tion was observed (Fig. 2a). Again, callus formation with a ‘cloud-like’
appearance was observed around the fracture site by CT scan taken atthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Case 1. An 88-year-old womanwho sustained a supracondylar fracture of the right femur. (a) Anteroposterior radiograph of the right knee soon after the fracture, and 2weeks and
8weeks after initiation of teriparatide therapy. Obvious callus formationwas visualized around the fracture site was observed at 2 and 8weeks after treatment (arrow). (b) CT scan of the
right knee taken 4 weeks after initiation of teriparatide therapy.
12 Y. Kim et al. / Bone Reports 3 (2015) 11–144 weeks (Fig. 2b). After 1 year, the initial callus diminished its volume
and replaced by a hard bony callus. We allowed the patient to start
partial weight bearing after 4 weeks. No side effects attributable to the
drug were observed during treatment.
2.3. Case 3
A 78-year-old man sustained a periprosthetic femoral fracture of
Vancouver type B2 after he fell and landed on his left side. He had pre-
viously undergone a left bipolar hemiarthroplasty 9 years earlier to treat
a femoral neck fracture and had been ambulating well. He had a previ-
ous history of thoracic and lumbar spine multiple compression frac-
tures, which were treated conservatively. He had no history of
treatment for osteoporosis. The patient was treated with stem revision
using a cemented long stem and cerclage wiring. After surgery, we ad-
ministered teriparatide. From 2 weeks after initiation of teriparatideFig. 2. Case 2. A 96-year-old woman who sustained a periprosthetic femoral fracture of the rig
eratively, and 2weeks, 8weeks, and 1 year after initiation of teriparatide therapy. Obvious callus
After 1 year, remodeling of the fracture callus was complete (arrow). (b) CT scan of the right ktherapy, a plain radiograph showed obvious callus formation, and
after 8 weeks, abundant callus formation was observed. After 1 year,
the initial callus diminished its volume and replaced by a hard bony cal-
lus (Fig. 3). No side effects attributable to thedrugwere observedduring
treatment.
3. Discussion
Our study is among the ﬁrst to report on the radiographic features of
teriparatide-induced healing of femoral insufﬁciency fractures. Most
previous case reports of teriparatide-induced fracture healing dealt
with the nonunion or delayed union of fractures (Chintamaneni et al.,
2010; Tamai et al., 2013; Ochi et al., 2013). Aspenberg et al described
a prospective, randomized, double blind study in postmenopausal
women who underwent conservative treatment for distal radial frac-
tures (Aspenberg et al., 2010). However, these authors did not preciselyht femur. (a) Anteroposterior radiograph of the right femur taken preoperatively, postop-
formation around the fracture sitewas observed at 2 and 8weeks after treatment (arrow).
nee taken 4 weeks after initiation of teriparatide therapy.
Fig. 3.Case 3. A 78-year-oldmanwho sustained a periprosthetic femoral fracture of the left femur. Anteroposterior radiographof the left femur takenpreoperatively, postoperatively, and 2
weeks, 8 weeks, and 1 year after initiation of teriparatide therapy. Obvious callus formation around the fracture site was observed at 2 and 8 weeks after treatment (arrow). After 1 year,
remodeling of the fracture callus was complete (arrow).
13Y. Kim et al. / Bone Reports 3 (2015) 11–14describe the radiographic features of the callus formation around the
radial fracture.
We identiﬁed several radiographic features around the femoral
fractures during the fracture healing period. First, the callus formation
was found at a very early stage in the treatment. Our cases commenced
treatment with teriparatide 1 day after surgery or the initiation of
conservative treatment. A plain radiograph at 2 weeks showed that
treatmentwith teriparatide substantially increased unusually abundant
callus formation around the fracture site. In femoral shaft fractures
treated with intramedullary nailing, the callus appeared at a mean of
3.9 weeks after surgery (Yamji et al., 2002). This result suggests that
the callus formation after teriparatide therapy was approximately
2 weeks more early than normal healing. Moreover, this callus forma-
tion progressed for 8 weeks and led to healing of the fracture. This
ﬁnding is supported by several previous reports that teriparatide
enhances the early proliferative response of chondroprogenitor and
osteoprogenitor cells in fracture healing (Barnes et al., 2008; Nakajima
et al., 2002). In general, it takes approximately 12 weeks for a femoral
shaft fracture to heal. A callus formation is seen on radiograph by
6 weeks after locked plating of distal femur fractures (Lujan et al.,
2010). In the Vancouver type B periprosthetic femoral fracture treated
with osteosynthesis or stem revision it takes 4 to 12months for fracture
healing (Pavlou; Corten et al., 2009). Some authors have shown that
teriparatide accelerates fracture healing by improving the bone quality
of fracture callus and by increasing endochondral and intramembranous
ossiﬁcation and bone remodeling in an animal model (Nakazawa et al.,
2005). Aspenberg et al. also showed that teriparatide had a strong effect
on early callus formation in distal radial fractures (Aspenberg and
Johansson, 2010). The increased amount of callus formation in the
early phase of fracture healing can have a signiﬁcant clinical beneﬁt in
some difﬁcult fracture cases (Yamji et al., 2002; Aspenberg and
Johansson, 2010).
Second, abundant callus formation was found circumferentially
around the femoral cortexwith a ‘cloud-like’ appearance on plain radio-
graphs and CT scans. This type of callus formation around the femoral
fracture site is unusual without teriparatide treatment. A plain radio-
graph showed the presence of bone bridges between the fragments.
We also observed that these bone bridges were found circumferentially
around the cortex.
Third, although this radiographic appearance of unusually abundant
callus formation resembled heterotopic ossiﬁcation or myositis
ossiﬁcans, remodeling of the callus formation was found to be part of
thenormal fracture healingprocess. After 1 year, the initial callus dimin-
ished its volume and replaced by a hard bony callus in cases 2 and 3(Figs. 2 and 3). Our ﬁndings indicated that cloud-like callus formation
was normal secondary fractures healing, and not the abnormal soft tis-
sue calciﬁcation. These results suggest that the enhanced early fracture
healing associated with treatment with teriparatide was followed by a
normal fracture healing process. Heterotopic ossiﬁcation is abnormal
formation of mature bone within extraskeletal soft tissues where bone
does not normally exist and is observed most frequently in the hip
joint (Garland, 1991; Subbarao and Garrison, 1999). Heterotopic ossiﬁ-
cation causes considerable morbidity due to swelling, pain, and loss of
range of motion (Naraghi et al., 1996; Thomas, 1992). In our cases,
clinical examination showed no signiﬁcant restriction in the range of
motion of the hip and knee joints, no swelling, and an ability to walk
without pain at the last follow-up. Furthermore, radiographic assess-
ment showed that remodeling of the callus induced by teriparatide
proceeded in the samemanner as normal fracture healing. Our ﬁndings
suggest that teriparatide-induced fracture healing seems to occur with-
in the normal physiological response to bone fracture.
Our cases showed some clinical features that the fractures occurred
from minor trauma in elderly patients who had comorbidities that
predisposed them to osteoporosis. In particular, the postmenopausal
women (cases 1 and 2) had signiﬁcant osteoporosis of the femur.
These patients had never been treated for osteoporosis. These insufﬁ-
ciency fractures occurred in the femoral diaphysis and metaphysis.
Based on their radiographic appearance during the healing process in-
duced by teriparatide, these femoral fractures appear to be different
fromdistal radius fractures. Tamai et al. reported the accelerated healing
of a femoral shaft fracture (Tamai et al., 2013). This case showed that
callus formation was observed 2 weeks after teriparatide treatment
and abundant callus formation was found, similar to our cases. A pro-
spective, randomized, double blind study of teriparatide treatment in
distal radial fractures showed signiﬁcantly accelerated fracture healing;
however, the periosteal callus formationwas not so abundant in the dis-
tal radius (Aspenberg et al., 2010).
Femoral insufﬁciency fractures around a prosthesis are one of the
most catastrophic complications of osteoporosis and are often difﬁcult
to treat (Pavlou et al., 2011). Moreover, osteoporotic fractures in the
elderly make it difﬁcult to achieve fracture healing. The positive effects
of teriparatide on fracture healing 2 weeks after surgery were observed
in our cases. The use of teriparatide as an adjuvant therapy for fracture
healing appears to be a promising form of treatment.
There are several limitations to this study. This small case series was
retrospective in design and the follow up period was short. The lack of a
patient control group for comparison illustrates the need for a prospec-
tive randomized control trial to determine whether there is a role for
14 Y. Kim et al. / Bone Reports 3 (2015) 11–14teriparatide therapy to enhance fracture healing in cases where the nat-
ural healing process might be compromised.
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